Company / Cash & Equivalents
Pulmatrix, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.5M
FY2025
5-year range
$9.5M / $53.8M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $19M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of -21.4%.
Declined from $19M to $10M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -35.6%
- 5-Year CAGR
- -21.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -21.4%, indicating a declining trend.
- In FY2025, cash & equivalents increased 0.0% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -2.56 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | +0.0% |
| FY2024 | $9.5M | -50.3% |
| FY2023 | $19.2M | -46.2% |
| FY2022 | $35.6M | -33.8% |
| FY2021 | $53.8M | +70.1% |
| FY2020 | $31.7M | +35.1% |
| FY2019 | $23.4M | +814.6% |
| FY2018 | $2.6M | -38.7% |
| FY2017 | $4.2M | -77.9% |
| FY2016 | $18.9M | +4091.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026